Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) Label Update Provides New Dosing Guidelines for Physicians, Allowing for Greater Flexibility in Treating CIDP Patients
The label update is based on open label extension data from the landmark PATH (Polyneuropathy And Treatment with Hizentra) study
News provided by
Share this article
Share this article
KING OF PRUSSIA, Pa., April 29, 2021 /PRNewswire/ Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Hizentra
® (Immune Globulin Subcutaneous [Human] 20% Liquid) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The approval, based on data from the PATH (Polyneuropathy And Treatment with Hizentra) Extension study, simplifies dosage adjustments between two safe and effective doses proven to prevent CIDP relapse - without the need for intravenous immune globulin treatment in the event of a relapse on the low dose. The P